The stock of Nektar Therapeutics (NKTR) has gone up by 16.08% for the week, with a -15.88% drop in the past month and a -21.27% drop in the past quarter. The volatility ratio for the week is 8.18%, and the volatility levels for the past 30 days are 12.21% for NKTR. The simple moving average for the past 20 days is 13.61% for NKTR’s stock, with a -33.81% simple moving average for the past 200 days.
Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?
Moreover, the 36-month beta value for NKTR is 0.63. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NKTR is 179.37M and currently, short sellers hold a 4.33% of that float. On April 24, 2025, NKTR’s average trading volume was 2.41M shares.
NKTR) stock’s latest price update
The stock of Nektar Therapeutics (NASDAQ: NKTR) has increased by 2.70 when compared to last closing price of 0.69.Despite this, the company has seen a gain of 16.08% in its stock price over the last five trading days. zacks.com reported 2025-04-11 that Nektar (NKTR) reported earnings 30 days ago. What’s next for the stock?
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with Jefferies repeating the rating for NKTR by listing it as a “Buy.” The predicted price for NKTR in the upcoming period, according to Jefferies is $2 based on the research report published on April 11, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $6. The rating they have provided for NKTR stocks is “Outperform” according to the report published on March 14th, 2025.
B. Riley Securities gave a rating of “Buy” to NKTR, setting the target price at $4 in the report published on January 08th of the current year.
NKTR Trading at -8.34% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.47% of loss for the given period.
Volatility was left at 12.21%, however, over the last 30 days, the volatility rate increased by 8.18%, as shares sank -12.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.29% upper at present.
During the last 5 trading sessions, NKTR rose by +15.08%, which changed the moving average for the period of 200-days by -43.69% in comparison to the 20-day moving average, which settled at $0.6197. In addition, Nektar Therapeutics saw -24.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from Zalevsky Jonathan, who sale 10,300 shares at the price of $1.01 back on Feb 19 ’25. After this action, Zalevsky Jonathan now owns 316,604 shares of Nektar Therapeutics, valued at $10,403 using the latest closing price.
Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 11,040 shares at $1.01 during a trade that took place back on Feb 19 ’25, which means that Wilson Mark Andrew is holding 324,292 shares at $11,150 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -0.92 for the present operating margin
- 0.69 for the gross margin
The net margin for Nektar Therapeutics stands at -1.21. The total capital return value is set at -0.38. Equity return is now at value -124.10, with -33.90 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -1.71. The debt to equity ratio resting at 1.69. The interest coverage ratio of the stock is -3.23.
Currently, EBITDA for the company is -86.7 million with net debt to EBITDA at -0.64. When we switch over and look at the enterprise to sales, we see a ratio of 1.92. The receivables turnover for the company is 61.17for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.26.
Conclusion
To wrap up, the performance of Nektar Therapeutics (NKTR) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
